Replies to post #56281 on Biotech Values

[dewophile]

fair enough, but i do think in general MNTA is a relatively high risk high reward play, particularly since the near term value driver is an FDA decision in an area that is breaking new ground
as an aside i still don't understand exactly what they do over and above traditional carbohydrate analysis (and carbohydrate chemistry), but i think the sandoz collaboration provides some reassurance there is something to it